Brazil Approves Human Trials of Vivaxin, First Malaria Vaccine Targeting P. vivax

Brazil's regulatory body has approved human clinical trials for Vivaxin, an experimental malaria vaccine developed by UFMG, USP, and Cristália. The vaccine targets Plasmodium vivax, the parasite responsible for over 60% of malaria infections in Latin America. This marks a significant step in malaria control, though efficacy and safety remain unproven in humans.